Cartesian Therapeutics Analyst Price Targets

Cartesian Therapeutics Inc

RNACNASDAQ

Trade with Public

$6.08

-0.19-3.03%

Dern. MÀJ: Oct 19, 4:00 PM

$6.08

-0.19-3.03%

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

Cartesian Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cartesian Therapeutics (RNAC).

Price Target Range — 11 Quarters

Analyst Consensus — 9 Analysts

9Buy

Consensus RatingBuy# Analysts9Avg. Consensus PT$36Upside to Avg. PT+493.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$25
Sep 29, 2026	Needham	Gil Blum	Maintained	Buy	$40
Aug 18, 2026	Wedbush	Martin Fan	Maintained	Outperform	$38
Jun 10, 2026	Wedbush	Martin Fan	Maintained	Outperform	$38
Jun 9, 2026	Needham	Gil Blum	Maintained	Buy	$40
Jun 9, 2026	BTIG	Julian Harrison	Maintained	Buy	$44
May 27, 2026	Wedbush	Martin Fan	Maintained	Outperform	$38
May 26, 2026	Needham	Gil Blum	PT Cut	Buy	$42→$40
May 12, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$30→$25
May 1, 2026	Wedbush	Martin Fan	Maintained	Outperform	$38
Mar 10, 2026	Wedbush	Martin Fan	Maintained	Outperform	$38
Mar 9, 2026	Cantor Fitzgerald	Kristen Kluska	Upgrade	Neutral→Overweight	$16
Mar 9, 2026	Needham	Gil Blum	Maintained	Buy	$42
Jan 9, 2026	Needham	Gil Blum	PT Raise	Buy	$40→$42
Nov 19, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$40→$30
Nov 14, 2025	BTIG	Julian Harrison	PT Raise	Buy	$42→$44
Jul 9, 2025	Wedbush	Martin Fan	Initiate	Outperform	$38
May 8, 2025	Needham	Gil Blum	PT Cut	Buy	$41→$40
Apr 9, 2025	Needham	Gil Blum	Maintained	Buy	$41
Apr 9, 2025	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Buy	$40

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $25 price target.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $40 price target.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $40 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target

BTIG analyst Julian Harrison reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $44 price target.

Benzinga Newsdesk

Cartesian Therapeutics Inc

Cartesian Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target

PRO
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

PRO
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

PRO
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

PRO
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

PRO
BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Cartesian Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target

PRO
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

PRO
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

PRO
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

PRO
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

PRO
BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target

People Also Watch

People Also Watch

Cartesian Therapeutics Inc

Cartesian Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target

PRONeedham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

PROWedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

PROWedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

PRONeedham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

PROBTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Cartesian Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target

PRONeedham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

PROWedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

PROWedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

PRONeedham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

PROBTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target

PRO
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

PRO
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

PRO
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

PRO
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

PRO
BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target

PRO
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

PRO
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

PRO
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

PRO
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

PRO
BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target